Literature DB >> 31522245

Association between plasma concentration of edoxaban determined by direct and indirect methods in Japanese patients with non-valvular atrial fibrillation (CVI ARO 7).

Shinya Suzuki1, Yoshiyuki Morishima2, Atsushi Takita3, Takayuki Otsuka4, Naoharu Yagi4, Takuto Arita4, Takeshi Yamashita4.   

Abstract

Direct oral anticoagulants, including edoxaban, primarily do not need routine monitoring of the anticoagulant effect. However, extremely high/low plasma concentrations of edoxaban (PC-Ed) should be properly evaluated, especially when patients under anticoagulation therapy are at an emergency state. For this purpose, PC-Ed determined by an anti-Xa assay (indirect PC-Ed) is more convenient and, therefore, more useful compared with PC-Ed determined by an LC-MS/MS (direct PC-Ed) in daily clinical practice. Consecutive 97 patients with non-valvular atrial fibrillation (NVAF) under edoxaban therapy were evaluated, in whom edoxaban 60/30 mg doses were prescribed for 48/49 patients, 71 (73.2%) were men, and the average age was 69 years. CHADS2 score 0, 1, and ≥ 2 were 26.8%, 44.3%, and 28.9%, while CHA2DS2-VASc score 0, 1, and ≥ 2 were 14.4%, 16.5%, and 69.1%, respectively. Median values of direct and indirect PC-Ed by LC-MS/MS and anti-Xa assay were 187.1 and 176.1 ng/mL at peak (2-4 h post-dose) and 14.4 and 17.5 ng/mL at trough (pre-dose), respectively. The PC-Ed at peak and trough by two methods were significantly correlated, and the correlation coefficients were r = 0.973 and 0.963 (both, p < 0.0001), respectively. By a Bland-Altman plot, mean differences between the direct and indirect PC-Ed [lower to upper percent limit of agreement] were - 4.87 [- 46.71 to 36.98] and 4.66 [- 1.37 to 10.69] ng/mL at peak and trough, respectively. Moreover, mean % error for difference between the direct and indirect PC-Ed [lower to upper percent limit of agreement] was - 1.22 [- 20.59 to 18.14] and 31.75 [- 14.03 to 77.53] % at peak and trough, respectively, where the % error extremely increased around the lower limit of detection (LLOD) in the anti-Xa assay. Strong similarity was observed between the direct and indirect PC-Ed, especially at peak. The indirect PC-Ed was higher than the direct PC-Ed, especially around the LLOD, suggesting the need for caution when we use the anti-Xa assay for measurement of trough PC-Ed (UMIN 000032492).

Entities:  

Keywords:  Anticoagulation; Atrial fibrillation; Edoxaban plasma concentration

Mesh:

Substances:

Year:  2019        PMID: 31522245     DOI: 10.1007/s00380-019-01501-2

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  17 in total

1.  Response of prothrombin time to rivaroxaban in Japanese patients with non-valvular atrial fibrillation: Characteristics of 5 representative reagents in Japan (CVI ARO 1).

Authors:  Shinya Suzuki; Takeshi Yamashita; Hidefumi Kasai; Takayuki Otsuka; Koichi Sagara
Journal:  Thromb Res       Date:  2016-12-27       Impact factor: 3.944

2.  Edoxaban: Impact on routine and specific coagulation assays. A practical laboratory guide.

Authors:  Jonathan Douxfils; Bernard Chatelain; Christian Chatelain; Jean-Michel Dogné; François Mullier
Journal:  Thromb Haemost       Date:  2015-10-29       Impact factor: 5.249

3.  Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans.

Authors:  Mohinder S Bathala; Hiroshi Masumoto; Toshihiro Oguma; Ling He; Chris Lowrie; Jeanne Mendell
Journal:  Drug Metab Dispos       Date:  2012-08-30       Impact factor: 3.922

4.  Comparison of anti-Xa and dilute Russell viper venom time assays in quantifying drug levels in patients on therapeutic doses of rivaroxaban.

Authors:  Robert C Gosselin; Dorothy M Adcock Funk; J Michael Taylor; Suzanne J Francart; Emily M Hawes; Kenneth D Friedman; Stephan Moll
Journal:  Arch Pathol Lab Med       Date:  2014-12       Impact factor: 5.534

5.  The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.

Authors:  Jan Steffel; Peter Verhamme; Tatjana S Potpara; Pierre Albaladejo; Matthias Antz; Lien Desteghe; Karl Georg Haeusler; Jonas Oldgren; Holger Reinecke; Vanessa Roldan-Schilling; Nigel Rowell; Peter Sinnaeve; Ronan Collins; A John Camm; Hein Heidbüchel
Journal:  Eur Heart J       Date:  2018-04-21       Impact factor: 29.983

Review 6.  Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication.

Authors:  Adam Cuker
Journal:  J Thromb Thrombolysis       Date:  2016-02       Impact factor: 2.300

7.  Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.

Authors:  Christian T Ruff; Robert P Giugliano; Eugene Braunwald; David A Morrow; Sabina A Murphy; Julia F Kuder; Naveen Deenadayalu; Petr Jarolim; Joshua Betcher; Minggao Shi; Karen Brown; Indravadan Patel; Michele Mercuri; Elliott M Antman
Journal:  Lancet       Date:  2015-03-11       Impact factor: 79.321

8.  DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles.

Authors:  T Furugohri; K Isobe; Y Honda; C Kamisato-Matsumoto; N Sugiyama; T Nagahara; Y Morishima; T Shibano
Journal:  J Thromb Haemost       Date:  2008-07-04       Impact factor: 5.824

9.  Study design of J-ELD AF: A multicenter prospective cohort study to investigate the efficacy and safety of apixaban in Japanese elderly patients.

Authors:  Masaharu Akao; Takeshi Yamashita; Ken Okumura
Journal:  J Cardiol       Date:  2016-01-21       Impact factor: 3.159

10.  Accuracy and consistency of anti-Xa activity measurement for determination of rivaroxaban plasma levels.

Authors:  J-D Studt; L Alberio; A Angelillo-Scherrer; L M Asmis; P Fontana; W Korte; A Mendez; P Schmid; H Stricker; D A Tsakiris; W A Wuillemin; M Nagler
Journal:  J Thromb Haemost       Date:  2017-07-17       Impact factor: 5.824

View more
  1 in total

1.  Changes in plasma concentrations of edoxaban and coagulation biomarkers according to thromboembolic risk and atrial fibrillation type in patients undergoing catheter ablation: Subanalysis of KYU-RABLE.

Authors:  Tetsuji Shinohara; Naohiko Takahashi; Yasushi Mukai; Tetsuya Kimura; Keita Yamaguchi; Atsushi Takita; Hideki Origasa; Ken Okumura
Journal:  J Arrhythm       Date:  2020-12-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.